Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.
Adenine
/ analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
/ genetics
Animals
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Dog Diseases
/ drug therapy
Dogs
Gene Expression Regulation, Neoplastic
/ drug effects
Histamine
/ metabolism
Immunoglobulin E
/ pharmacology
Mastocytoma
/ drug therapy
Piperidines
Pyrazoles
/ pharmacology
Pyrimidines
/ pharmacology
STAT5 Transcription Factor
/ genetics
BTK
IgE
canine neoplastic mast cells
histamine release
ibrutinib
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
01
04
2019
revised:
02
07
2019
accepted:
03
07
2019
pubmed:
10
7
2019
medline:
7
3
2020
entrez:
10
7
2019
Statut:
ppublish
Résumé
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is effective in the treatment of human chronic lymphocytic leukaemia and mantle cell lymphoma. Recent data have shown that ibrutinib also blocks IgE-dependent activation and histamine release in human basophils (BAs) and mast cells (MCs). The aim of this study was to investigate whether BTK serves as a novel therapeutic target in canine mast cell tumours (MCTs). We evaluated the effects of ibrutinib on two canine MC lines, C2 and NI-1 and on primary MCs obtained from canine MCTs (n = 3). Using flow cytometry, we found that ibrutinib suppresses phosphorylation of BTK and of downstream STAT5 in both MC lines. In addition, ibrutinib decreased proliferation of neoplastic MCs, with IC
Identifiants
pubmed: 31286638
doi: 10.1111/vco.12520
pmc: PMC6900099
doi:
Substances chimiques
Piperidines
0
Pyrazoles
0
Pyrimidines
0
STAT5 Transcription Factor
0
ibrutinib
1X70OSD4VX
Immunoglobulin E
37341-29-0
Histamine
820484N8I3
Agammaglobulinaemia Tyrosine Kinase
EC 2.7.10.2
Adenine
JAC85A2161
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
553-561Subventions
Organisme : Austrian Science Fund
ID : DK W1248-B30
Organisme : Austrian Science Fund
ID : SFB F4701-B20
Organisme : Austrian Science Fund
ID : SFB F4704-B20
Informations de copyright
© 2019 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.
Références
Haematologica. 2013 Sep;98(9):1450-7
pubmed: 23539538
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80
pubmed: 20615965
Vet Comp Oncol. 2019 Mar;17(1):1-10
pubmed: 30136349
Br J Dermatol. 2006 Dec;155(6):1109-23
pubmed: 17107377
J Leukoc Biol. 2009 Aug;86(2):313-25
pubmed: 19436043
Vet Rec. 2013 Nov 2;173(17):423
pubmed: 24114734
BMC Vet Res. 2014 May 06;10:105
pubmed: 24885200
Ann Oncol. 2017 Oct 1;28(10):2367-2376
pubmed: 28945834
Vet Dermatol. 2008 Dec;19(6):321-39
pubmed: 18980632
Vet Comp Oncol. 2015 Sep;13(3):267-80
pubmed: 23721492
J Invest Dermatol. 1991 Mar;96(3 Suppl):2S-4S; discussion 4S, 60S-65S
pubmed: 16799601
Allergy. 2012 Jul;67(7):858-68
pubmed: 22583069
Immunol Rev. 2009 Mar;228(1):149-69
pubmed: 19290926
Leuk Res. 2001 Jul;25(7):603-25
pubmed: 11377686
Allergy. 2017 Nov;72(11):1666-1676
pubmed: 28328081
Vet Pathol. 1984 Sep;21(5):469-74
pubmed: 6435301
Vet Pathol. 2004 Jul;41(4):371-7
pubmed: 15232137
Leuk Res. 2013 Oct;37(10):1271-7
pubmed: 23962569
J Vet Emerg Crit Care (San Antonio). 2009 Aug;19(4):311-28
pubmed: 25164630
Top Companion Anim Med. 2009 Aug;24(3):106-12
pubmed: 19732728
J Immunol. 2008 Dec 1;181(11):7706-12
pubmed: 19017959
Clin Cancer Res. 2017 Jul 15;23(14):3734-3743
pubmed: 28034907
Haematologica. 2011 May;96(5):672-80
pubmed: 21242189
Clin Cancer Res. 2009 Jun 1;15(11):3856-65
pubmed: 19470739
Vet J. 2016 Sep;215:43-54
pubmed: 27372911
Ann Hematol. 2002 Dec;81(12):677-90
pubmed: 12483363
Semin Cancer Biol. 2013 Dec;23(6):410-21
pubmed: 24060900
Oncotarget. 2016 Jan 26;7(4):4598-610
pubmed: 26717038
J Vet Intern Med. 2008 Nov-Dec;22(6):1301-9
pubmed: 18823406
Leukemia. 2014 Mar;28(3):649-57
pubmed: 24270740
Vet Q. 2004 Dec;26(4):156-69
pubmed: 15663212
Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9175-9
pubmed: 7522330
Vet Clin North Am Small Anim Pract. 2006 Jan;36(1):175-84, vii-viii
pubmed: 16364783
Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):187-98
pubmed: 11553379
Vet Comp Oncol. 2012 Sep;10(3):e1-e29
pubmed: 22882486
Oncotarget. 2017 Feb 21;8(8):12953-12967
pubmed: 28088788
Int Rev Immunol. 2012 Apr;31(2):119-32
pubmed: 22449073
J Vet Med Sci. 2006 Jun;68(6):581-7
pubmed: 16820715
Vet Comp Oncol. 2018 Mar;16(1):55-68
pubmed: 28397975
Vet Comp Oncol. 2019 Dec;17(4):553-561
pubmed: 31286638
Am J Respir Cell Mol Biol. 1990 Nov;3(5):413-20
pubmed: 2121170
Blood. 2011 Aug 18;118(7):1885-98
pubmed: 21680801
Vet Comp Oncol. 2017 Dec;15(4):1240-1256
pubmed: 27507155
Exp Hematol. 1999 Apr;27(4):689-97
pubmed: 10210327
N Engl J Med. 2016 Jun 30;374(26):2530-41
pubmed: 27355533
Leuk Res. 1988;12(4):345-55
pubmed: 3131594
Int Immunopharmacol. 2011 Apr;11(4):475-9
pubmed: 21238622
Am J Vet Res. 2002 May;63(5):763-6
pubmed: 12013481
Exp Hematol. 2007 Oct;35(10):1510-21
pubmed: 17681669
J Vet Intern Med. 1999 Sep-Oct;13(5):491-7
pubmed: 10499735
J Small Anim Pract. 2002 Jun;43(6):240-6
pubmed: 12074288
J Am Vet Med Assoc. 2004 Jan 1;224(1):79-82
pubmed: 14710881
Curr Treat Options Oncol. 2014 Jun;15(2):226-37
pubmed: 24481980
J Natl Cancer Inst. 2013 Apr 3;105(7):452-8
pubmed: 23434901
Nat Rev Cancer. 2014 Apr;14(4):219-32
pubmed: 24658273
Vet Clin North Am Small Anim Pract. 2003 May;33(3):473-89, v
pubmed: 12852232
Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):199-204
pubmed: 11553380
Oncogene. 2018 Nov;37(47):6180-6194
pubmed: 30013190